Etofibrate (BioDeep_00000178933)

   

human metabolite blood metabolite


代谢物信息卡片


2-(Pyridine-3-carbonyloxy)ethyl 2-(4-chlorophenoxy)-2-methylpropanoic acid

化学式: C18H18ClNO5 (363.08734480000004)
中文名称: 依托贝特
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC(C)(C(=O)OCCOC(=O)C1=CN=CC=C1)OC2=CC=C(C=C2)Cl
InChI: InChI=1S/C18H18ClNO5/c1-18(2,25-15-7-5-14(19)6-8-15)17(22)24-11-10-23-16(21)13-4-3-9-20-12-13/h3-9,12H,10-11H2,1-2H3

描述信息

C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent > C98150 - Fibrate Antilipidemic Agent
C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AB - Fibrates
D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents
D009676 - Noxae > D000963 - Antimetabolites

同义名列表

7 个代谢物同义名

2-(Pyridine-3-carbonyloxy)ethyl 2-(4-chlorophenoxy)-2-methylpropanoic acid; 2-(pyridine-3-carbonyloxy)ethyl 2-(4-chlorophenoxy)-2-methylpropanoate; Etofibrate hydrochloride; Etofibric acid; Etofibrate; Lipo-merz; Tricerol



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Tobias Jakob, Alain J Nordmann, Stefan Schandelmaier, Ignacio Ferreira-González, Matthias Briel. Fibrates for primary prevention of cardiovascular disease events. The Cochrane database of systematic reviews. 2016 11; 11(?):CD009753. doi: 10.1002/14651858.cd009753.pub2. [PMID: 27849333]
  • Eloísa Marchi Dos Anjos, Karina Pfrimer, Alcyone Artioli Machado, Selma Freire de Carvalho Cunha, Roberta Garcia Salomão, Jacqueline Pontes Monteiro. Nutritional and metabolic status of HIV-positive patients with lipodystrophy during one year of follow-up. Clinics (Sao Paulo, Brazil). 2011; 66(3):407-10. doi: 10.1590/s1807-59322011000300007. [PMID: 21552663]
  • K-H Emmerich, N Poritis, I Stelmane, M Klindzane, H Erbler, J Goldsteine, R Görtelmeyer. [Efficacy and safety of etofibrate in patients with non-proliferative diabetic retinopathy]. Klinische Monatsblatter fur Augenheilkunde. 2009 Jul; 226(7):561-7. doi: 10.1055/s-0028-1109516. [PMID: 19644802]
  • Barbara Palumbo, Anthony Oguogho, Renato Palumbo, Helmut Sinzinger. Etofibrate enhances 123I-LDL-binding in human liver. Hellenic journal of nuclear medicine. 2009 Jan; 12(1):13-6. doi: NULL. [PMID: 19330175]
  • Mohamed A Korany, Ismail I Hewala, Karim M Abdel-Hay. Determination of etofibrate, fenofibrate, and atorvastatin in pharmaceutical preparations and plasma using differential pulse polarographic and square wave voltammetric techniques. Journal of AOAC International. 2008 Sep; 91(5):1051-8. doi: NULL. [PMID: 18980118]
  • Konstantinos Tziomalos, Vasilios G Athyros. Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review. International journal of nanomedicine. 2006; 1(2):129-47. doi: 10.2147/nano.2006.1.2.129. [PMID: 17722529]
  • H C Geiss, M Dietlein, K G Parhofer. Influence of etofibrate on LDL-subtype distribution in patients with diabetic dyslipoproteinemia. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. 2003 Sep; 111(6):322-4. doi: 10.1055/s-2003-42720. [PMID: 14520596]
  • H Fr Schröder. Mass spectrometric monitoring of the degradation and elimination efficiency for hardly eliminable and hardly biodegradable polar compounds by membrane bioreactors. Water science and technology : a journal of the International Association on Water Pollution Research. 2002; 46(3):57-64. doi: 10.2166/wst.2002.0054. [PMID: 12227604]
  • A C Sposito, A P Mansur, R C Maranhão, C R Rodrigues-Sobrinho, O R Coelho, J A Ramires. Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas. 2001 Feb; 34(2):177-82. doi: 10.1590/s0100-879x2001000200004. [PMID: 11175492]
  • A C Spósito, R C Maranhão, C G Vinagre, R D Santos, J A Ramires. Effects of etofibrate upon the metabolism of chylomicron-like emulsions in patients with coronary artery disease. Atherosclerosis. 2001 Feb; 154(2):455-61. doi: 10.1016/s0021-9150(00)00491-3. [PMID: 11166779]
  • A Steinmetz, S Fenselau, J Schrezenmeir. Treatment of dyslipoproteinemia in the metabolic syndrome. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. 2001; 109(4):S548-59. doi: 10.1055/s-2001-15117. [PMID: 11453042]
  • A C Spósito, B Caramelli, C V Serrano, A P Mansur, J A Ramires. Effect of niacin and etofibrate association on subjects with coronary artery disease and serum high-density lipoprotein cholesterol <35 mg/dl. The American journal of cardiology. 1999 Jan; 83(1):98-100, A8. doi: 10.1016/s0002-9149(98)00787-5. [PMID: 10073791]
  • M Jastrzebska, B Torbus-Lisiecka, J Pieczul-Mróz, K Chelstowski, J Kopciewicz, M Naruszewicz. Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome. International journal of clinical pharmacology research. 1999; 19(1):19-25. doi: NULL. [PMID: 10450539]
  • J E dos Santos, A A Loures-Vale, J P Novazzi, L M Rabelo, T L Martinez. [Evaluation of efficacy and safety of etofibrate in primary hyperlipidemia. A multicenter study]. Arquivos brasileiros de cardiologia. 1996 Dec; 67(6):419-22. doi: ". [PMID: 9246832]
  • J E Fincham, G Quack, P Wülfroth, A J Benadé. Confirmation of efficacy of etofibrate against peripheral atherosclerosis in non-human primates which model human lesion types I-VII. Arzneimittel-Forschung. 1996 May; 46(5):519-25. doi: . [PMID: 8737639]
  • F A Fonseca, J P Novazzi, M S Cendoroglo, M Duarte, L E Almeida Pinto, L M Rabelo, T L da Rocha Martinez. [Lipid changes of fibrinogen and of platelet aggregation induced by etofibrate]. Arquivos brasileiros de cardiologia. 1996 Jan; 66(1):33-5. doi: ". [PMID: 8731322]
  • R Kinscherf, J Metz, P Wülfroth. Etofibrate suppresses neointima formation of the ballooned common carotid artery of rats. Naunyn-Schmiedeberg's archives of pharmacology. 1995 Oct; 352(4):424-8. doi: 10.1007/bf00172780. [PMID: 8532071]
  • C Bocos, E Orozco, M Castro, G Quack, E Herrera. Effect of etofibrate on bile production in the normolipidemic rat. General pharmacology. 1995 May; 26(3):537-42. doi: 10.1016/0306-3623(94)00225-c. [PMID: 7789727]
  • R Raedsch, J Plachky, N Wolf, G Simonis. Biliary lipids, lithogenic index and biliary drug concentrations during etofibrate and bezafibrate treatment. European journal of drug metabolism and pharmacokinetics. 1995 Apr; 20(2):113-8. doi: 10.1007/bf03226364. [PMID: 8582435]
  • H Freyberger, E Schifferdecker, H Schatz. [Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipemic agent]. Medizinische Klinik (Munich, Germany : 1983). 1994 Nov; 89(11):594-7, 633. doi: NULL. [PMID: 7815987]
  • H R Wolf. Efficacy and tolerability of etofibrate and gemfibrozil in combined hyperlipidaemia. Drugs under experimental and clinical research. 1994; 20(3):109-13. doi: ". [PMID: 7956717]
  • V T Bartz, J Gatz, C Slotty, C Schröter, R Töle, P Wand. [Long-term treatment of hyperlipoproteinemia with etofibrate]. Fortschritte der Medizin. 1993 Sep; 111(25):398-400. doi: ". [PMID: 8406286]
  • I Virgolini, E Koller, S Li, Q Yang, M Banyai, F Rauscha, J Pidlich, W Pirker, H Sinzinger. Etofibrate increases binding of low and high density lipoprotein to human platelets of patients with type II hyperlipoproteinemia. Atherosclerosis. 1993 Sep; 102(2):217-26. doi: 10.1016/0021-9150(93)90164-p. [PMID: 8251008]
  • C Bocos, M Castro, G Quack, E Herrera. Studies with etofibrate in the rat. Part II: A comparison of the effects of prolonged and acute administration on plasma lipids, liver enzymes and adipose tissue lipolysis. Biochimica et biophysica acta. 1993 Jul; 1168(3):340-7. doi: 10.1016/0005-2760(93)90191-b. [PMID: 8323974]
  • P Wülfroth, C M Richter, M Burkard, K Huth, G Quack. Etofibrate treatment alters low density lipoprotein susceptibility to lipid peroxidation. Drugs under experimental and clinical research. 1992; 18(11-12):469-74. doi: NULL. [PMID: 1308472]
  • M Horváth, Z Mezey, A Jósfay, I Nánay, M Varsányi, S Geró. The effect of some drugs on in vitro cellular immune reactions and on circulating immune complexes in patients with myocardial infarction. Journal of investigational allergology & clinical immunology. 1991 Dec; 1(6):404-10. doi: NULL. [PMID: 1669600]
  • L Kłosiewicz-Latoszek, W B Szostak. Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia. European journal of clinical pharmacology. 1991; 40(1):33-41. doi: 10.1007/bf00315136. [PMID: 2060543]
  • M Horváth, M Varsányl, N Jovanovich, L Romics, S Gerö. The effect of Etofibrate (Lipo-Merz) on 'in vitro' cellular immune response and on lipid parameters of men with myocardial infarction and with arteriosclerosis obliterans. Allergologia et immunopathologia. 1990 Mar; 18(2):95-9. doi: NULL. [PMID: 2371944]
  • E Betz, G Quack. Effect of etofibrate on the development and the regression of atheromas in a rabbit model of atherosclerosis. VASA. Zeitschrift fur Gefasskrankheiten. 1990; 19(2):157-60. doi: NULL. [PMID: 2371790]
  • ". [Lipid therapy with etofibrate. Reduction of multiple risk factors with an active substance. Report of an international seminar. 8-11 November 1989, Houston, Texas]. Fortschritte der Medizin. Supplement : die Kongressinformation fur die Praxis. 1990; 85(?):1-15. doi: ". [PMID: 2338325]
  • E De Fabiani, M Crestani, B Malavasi, M Del Puppo, F Farina, C Armocida, S Bellentani, G Quack, E Bosisio. The effect of etofibrate on cholesterol and bile acid metabolism in the hamster. Pharmacological research. 1989 Sep; 21(5):567-76. doi: 10.1016/1043-6618(89)90198-9. [PMID: 2594613]
  • A Dembińska-Kieć, E Kostka-Trabka, L Grodzińska, K Bieroń, A Kedzior, M Basista, A Zmuda, E Trabka, M Slawiński, H Czarnecka. [Effectiveness of etofibrate in arteriosclerosis obliterans. Pilot study in hyperlipidemic patients with arteriosclerosis obliterans]. Fortschritte der Medizin. 1989 Jul; 107(20):450-2. doi: NULL. [PMID: 2767596]
  • E Herrera, M A Lasunción, M Castro, D Gómez-Coronado, A Martín, G Quack. Studies with etofibrate in the rat. Part I: Effects on glycerol, free fatty acid and triacylglycerol metabolism. Biochimica et biophysica acta. 1988 Nov; 963(1):42-52. doi: 10.1016/0005-2760(88)90336-0. [PMID: 3179329]
  • J J Series, M J Caslake, C Kilday, A Cruickshank, T Demant, C J Packard, J Shepherd. Influence of etofibrate on low density lipoprotein metabolism. Atherosclerosis. 1988 Feb; 69(2-3):233-9. doi: 10.1016/0021-9150(88)90019-6. [PMID: 3348843]
  • R H Palmer. Effects of fibric acid derivatives on biliary lipid composition. The American journal of medicine. 1987 Nov; 83(5B):37-43. doi: 10.1016/0002-9343(87)90869-2. [PMID: 3318452]
  • E Betz, H Hämmerle. Effect of etofibrate and its metabolites on atheromas of rabbits and on smooth muscle cell cultures. Arzneimittel-Forschung. 1986; 36(1):92-8. doi: NULL. [PMID: 3954822]
  • E R Garrett, P Altmayer. Disposition of etofibrate, clofibric and nicotinic acid esters, and their products in dogs. Journal of pharmaceutical sciences. 1985 Mar; 74(3):295-9. doi: 10.1002/jps.2600740314. [PMID: 4009437]
  • A R Waller, L F Chasseaud, T Taylor, W Schatton. Bioavailability studies of etofibrate in rhesus monkeys. Arzneimittel-Forschung. 1985; 35(2):489-92. doi: . [PMID: 4039571]
  • K I Johnson, H J Hoppe, W Schatton. Relative bioavailability of etofibrate. A comparison of an acute and a new sustained release formulation. Arzneimittel-Forschung. 1984; 34(12):1785-7. doi: . [PMID: 6543315]
  • P Altmayer, E R Garrett. Plasmolysis, red blood cell partitioning, and plasma protein binding of etofibrate, clofibrate, and their degradation products. Journal of pharmaceutical sciences. 1983 Nov; 72(11):1309-18. doi: 10.1002/jps.2600721119. [PMID: 6644594]
  • R Paoletti, G Franceschini, C R Sirtori. Influence of bezafibrate, fenofibrate, nicotinic acid and etofibrate on plasma high-density lipoprotein levels. The American journal of cardiology. 1983 Aug; 52(4):21B-27B. doi: 10.1016/0002-9149(83)90653-7. [PMID: 6351577]
  • P Udelhoven. [Lipid lowering improved? Therapeutic progress by using biological mechanisms]. Die Medizinische Welt. 1982 Sep; 33(36):3. doi: ". [PMID: 7132677]
  • K Machalke, S Djaja, E Richter. [Lipid-lowering effect of etofibrate, bezafibrate and xanthinol nicotinate in patients with hyperlipoproteinemias]. Therapie der Gegenwart. 1982 May; 121(5):301-11. doi: ". [PMID: 6953613]
  • E R Garrett, M R Gardner. Predictions of stability in pharmaceutical preparations XIX: Stability evaluation and bioanalysis of clofibric acid esters by high-pressure liquid chromatography. Journal of pharmaceutical sciences. 1982 Jan; 71(1):14-25. doi: 10.1002/jps.2600710105. [PMID: 7057373]
  • D P Mertz. [Clofibrate therapy in hypercholesterolemia. Reports on medium-long-term movements of HDL- cholesterol by the action of clofibrate]. Fortschritte der Medizin. 1980 Dec; 98(45):1761-6. doi: NULL. [PMID: 7461569]
  • I Füsgen, J D Summa. [An alternative in the therapy of primary hyperlipemias: etofibrate in depot preparations]. Medizinische Klinik. 1980 Nov; 75(23):823-5. doi: NULL. [PMID: 7442597]
  • M P Ortega, C Sunkel, M Armijo, J G Priego. Effects of etofibrate on platelet function: in vitro studies in human plasma. Thrombosis research. 1980 Aug; 19(3):409-16. doi: 10.1016/0049-3848(80)90269-8. [PMID: 7001672]
  • W Steger. [Therapy of lipoproteinemia. Comparison between Lipo-Merz retard and a commercial combination drug]. Fortschritte der Medizin. 1980 May; 98(18):(718-20). doi: NULL. [PMID: 7390386]
  • L Altomonte, G Mingrone, G Ghirlanda, R Manna, A Rebuzzi, M A Pala, A V Greco. [Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)]. Minerva medica. 1980 Feb; 71(4):273-8. doi: ". [PMID: 7354946]
  • H Kaffarnik, J Schneider, R Schubotz, P Zöfel. [Longterm therapy and etofibrate (author's transl)]. MMW, Munchener medizinische Wochenschrift. 1980 Jan; 122(3):95-8. doi: NULL. [PMID: 6767931]
  • H Kaffarnik, J Schneider, R Schubotz, P Zöfel, L Hausmann, K M Goebel. Long-term treatment of hyperlipoproteinemia with etofibrate: clinical observations. Artery. 1980; 8(6):537-46. doi: NULL. [PMID: 6114725]
  • H Oelschläger, D Rothley, M Ewert, P Nachev. [Stability of antilipidemic etofibrate and its metabolites towards gastrointestinal and blood hydrolases (author's transl)]. Arzneimittel-Forschung. 1980; 30(6):984-8. doi: NULL. [PMID: 7191278]
  • D P Mertz, H Loewer, I Suermann. [The range and lipid-lowering effect of etofibrate as a retard-preparation in patients with hyperlipoproteinemia type IIa (author's transl)]. Medizinische Klinik. 1979 Dec; 74(51-52):1953-6. doi: NULL. [PMID: 542179]
  • A Gustafson. Treatment of hyperlipoproteinemia type II with etofibrate. International journal of clinical pharmacology and biopharmacy. 1979 Dec; 17(12):498-502. doi: NULL. [PMID: 528096]
  • J G Priego, M L Maroto, M Piña, R E Catalan. Effects of etofibrate, clofibrate and nicotinic acid on lipid metabolism in normolipemic rats. General pharmacology. 1979; 10(3):215-9. doi: 10.1016/0306-3623(79)90092-2. [PMID: 467961]
  • J G Priego, M L Maroto, M Piña, R E Catalán. Effects of etofibrate, clofibrate and nicotinic acid on lipid metabolism in hyperlipidemic rats. General pharmacology. 1979; 10(4):315-8. doi: 10.1016/0306-3623(79)90059-4. [PMID: 488666]
  • M Otsuki, C Sakamoto, M Maeda, H Yuu, T Yamasaki, K Okano, S Baba. [The effect of secretin on exocrine and endocrine pancreas. Part I: plasma secretin concentration and pancreatic exocrine secretion after intravenous secretin or intraduodenal HCl and 1-phenyl-1-hydroxy-n-pentane administration (author's transl)]. Nihon Naibunpi Gakkai zasshi. 1978 Oct; 54(10):1116-24. doi: 10.1507/endocrine1927.54.10_1116. [PMID: 31307]
  • . . . . doi: . [PMID: 18288277]